Take a look at this month’s industry headlines including news from ViiV Healthcare on long-acting and single dose formulations, sales for Eli Lilly and the possible development of a plague vaccine.
Antiretroviral therapy with efavirenz in HIV-positive pregnant women has been reported to increase the risk of neurological conditions in offspring.
ViiV healthcare has announced results of a 100-week Phase lll program and demonstrated the success of the first two-drug regimen, Juluca®.
In top-line results from a Phase IIa study, Abivax has reported mixed data, although ABX464 did appear to reduce HIV DNA in blood and rectal samples at a higher dose.
A new study has highlighted the neurological damage caused by exposure to HIV without antiretroviral therapy.
Mylan N.V have announced they’ll be launching their third HIV combination in the US, following FDA approval of their once-daily treatment Symfi™.
For International Women’s Day, we spoke to Sharon Lewin about her typical day, who inspires her and her great deal of international travel!
Researchers have developed a drug delivery system that could allow antiretroviral drugs for HIV to be administered only once a week, potentially making it easier for patients to adhere to drug regimens.
Despite significant advances in the treatment of human immunodeficiency virus (HIV), there remain challenges. This review highlights recent advances in the application of nanotechnology to drug delivery, specifically with the purpose of improving HIV therapy.
A child born with HIV has been found to suppress the infection without the reliance on conventional antiretroviral therapy; this may have future implications on the therapeutic approaches to HIV especially in infants.
